Intake Forms for Fertility Clinics: What Reproductive Endocrinology Practices Must Document Before the First Cycle
A couple walks into a reproductive endocrinology practice for their first consultation. They have been trying to conceive for fourteen months. The referring OB-GYN sent over a packet of labs — some of them six months old — and a note that says "infertility workup." The woman has a history of endometriosis. The man had a varicocele repair three years ago. Neither of them has been asked, in any structured way, about their full reproductive history, previous treatment attempts, genetic background, psychological readiness, or what they want to happen to cryopreserved embryos if their marriage ends.
All of that information needs to be captured before the first monitoring ultrasound, before the first hormone panel is drawn, and certainly before any consent for IVF, IUI, or egg freezing is signed. The intake process at a fertility clinic is not a formality — it is the clinical, legal, and regulatory foundation on which every subsequent treatment decision rests. Get it wrong, and you are building a treatment plan on incomplete data while exposing the practice to liability that no malpractice carrier wants to underwrite.
Here is what a fertility clinic intake form needs to capture, why each element matters, and where the documentation gaps tend to appear in practices that treat intake as a clerical task rather than a clinical one.
Reproductive history documentation: both partners, full depth
Fertility treatment is unusual in medicine because the "patient" is often a couple, and the clinical picture is incomplete if you only document one partner's history. A woman with unexplained infertility whose male partner has never had a semen analysis is not a case of unexplained infertility — it is an incomplete workup. Your intake form needs to capture reproductive history from both partners in parallel, not sequentially.
Female partner reproductive history
The female partner's reproductive history drives the initial diagnostic framework and directly influences protocol selection. Document thoroughly:
- Menstrual history — age at menarche, cycle length and regularity, duration and flow volume, dysmenorrhea severity, and any recent changes. A woman who reports her cycles were regular until six months ago when they became unpredictable at age 38 is telling you something different than a woman who has always had 45-day cycles. Both matter, but the clinical response is different.
- Pregnancy history — every pregnancy, including miscarriages, ectopic pregnancies, terminations, and live births. For each: gestational age at outcome, mode of delivery, any complications (preeclampsia, gestational diabetes, preterm labor, postpartum hemorrhage), birth weight, and whether conception was spontaneous or assisted. A history of two first-trimester losses changes the workup entirely — you are now screening for antiphospholipid syndrome, uterine anomalies, and chromosomal issues before you treat the infertility.
- Gynecologic surgical history — myomectomy, ovarian cystectomy, tubal surgery, endometriosis excision or ablation, hysteroscopy, D&C, LEEP or cone biopsy. Each of these affects the reproductive tract and may change how you approach stimulation, retrieval, or transfer. A patient who had bilateral ovarian cystectomies for endometriomas may have significantly reduced ovarian reserve — her AMH and antral follicle count will tell you, but you need to know to look.
- Known diagnoses — PCOS, endometriosis (stage if known), premature ovarian insufficiency, uterine fibroids (location and size), tubal factor, diminished ovarian reserve, thyroid disorders, hyperprolactinemia. These are not just medical history items — they are protocol determinants. PCOS patients need different stimulation approaches than DOR patients. Endometriosis may warrant suppression before transfer.
- Contraceptive history — current and past methods, duration of use, and time since discontinuation. A woman who discontinued hormonal contraception two months ago and has not had a natural cycle yet is in a different physiological state than one who stopped the pill eighteen months ago and has been cycling regularly since.
Male partner reproductive history
Male factor contributes to roughly 40-50% of infertility cases, yet many clinics treat male intake documentation as an afterthought — a few questions tacked onto the end of the female partner's form. That approach misses critical information:
- Previous semen analyses — dates, results (count, motility, morphology, volume), and the lab that performed them. A single semen analysis is a snapshot. Two or three analyses, especially if they show declining parameters, tell a trajectory story.
- Urologic history — varicocele (diagnosed, treated, or untreated), cryptorchidism, testicular torsion, epididymitis, prostatitis, hernia repair, vasectomy or reversal. Each of these has direct implications for sperm production or transport. A man with a history of bilateral cryptorchidism corrected at age 8 has a different fertility prognosis than one with a unilateral varicocele repaired last year.
- Medications and exposures — testosterone supplementation (which suppresses spermatogenesis and is one of the most common iatrogenic causes of male infertility), anabolic steroids, finasteride, alpha-blockers, chemotherapy history, radiation exposure, occupational chemical exposures, and excessive heat exposure (hot tubs, saunas, laptop use). Testosterone replacement therapy is so frequently overlooked as a cause of azoospermia that your intake form should ask about it specifically, not bury it in a general medication list.
- Sexual function — erectile dysfunction, ejaculatory disorders (retrograde ejaculation, anejaculation), frequency of intercourse, and whether intercourse is timed to ovulation. These questions are uncomfortable for patients and easy for clinicians to skip. They are also diagnostically essential. A couple reporting twelve months of infertility who, upon closer questioning, are having intercourse twice a month with no ovulation tracking may not have a fertility problem — they have a timing problem.
- Lifestyle factors — tobacco, alcohol, marijuana, and recreational drug use (each affects semen parameters differently), BMI, exercise habits, and stress levels. Document these for both partners, not just the female.
Previous fertility treatment history and outcomes
Patients who come to your practice from another fertility clinic bring the most valuable data set you will ever receive — a record of what has already been tried and how their body responded. Failure to capture this in detail at intake means you may repeat protocols that already failed or miss information that would have changed your approach:
- Previous IUI cycles — number of cycles, whether natural or medicated, medication used (clomiphene, letrozole, gonadotropins), trigger type, sperm source (partner or donor), sperm count at insemination, and outcome of each cycle. Three failed IUI cycles with good sperm counts suggest the issue is not at the cervical level and further IUI is unlikely to succeed.
- Previous IVF cycles — this is the most data-rich section of the intake. For each cycle: stimulation protocol (antagonist, long lupron, flare, mini-IVF), total gonadotropin dose, number of follicles at trigger, number of eggs retrieved, number mature (MII), fertilization method (conventional IVF or ICSI), fertilization rate, number and quality of embryos on day 3 and day 5/6, number transferred, number frozen, PGT results if applicable, transfer date relative to trigger, endometrial thickness at transfer, progesterone support protocol, beta-hCG result, and pregnancy outcome if positive.
- Response patterns — was the patient a poor responder, normal responder, or hyper-responder? Did she develop OHSS? Was cycle cancellation ever necessary? Did embryos arrest at a particular developmental stage? Were there recurrent implantation failures? This pattern data is as important as the raw numbers.
- Records release authorization — your intake form should include authorization for the patient to release records from their previous clinic, including lab results, ultrasound reports, operative notes, and embryology records. Without these, you are relying on patient recall, which is unreliable for the specific numerical data you need.
Hormonal evaluation and lab work coordination
Fertility patients arrive with lab results from multiple providers, drawn at different points in different cycles, using different lab reference ranges. Your intake form needs to both capture what already exists and identify what needs to be redrawn:
- Day 2-3 labs — FSH, LH, estradiol, AMH. These are the core ovarian reserve markers. AMH is cycle-independent, but FSH and estradiol must be drawn early in the follicular phase to be interpretable. If the patient's FSH was drawn on day 10, it is not clinically useful for reserve assessment. Your intake form should capture the cycle day the labs were drawn, not just the values.
- Thyroid panel — TSH, free T4, and thyroid antibodies (anti-TPO, anti-thyroglobulin). Subclinical hypothyroidism affects implantation and early pregnancy maintenance. ASRM recommends TSH below 2.5 mIU/L for patients attempting conception. If the patient's TSH from six months ago was 3.8, you need to address that before starting treatment.
- Prolactin — hyperprolactinemia suppresses ovulation. A mildly elevated prolactin may be a drawing artifact (stress, recent breast exam, timing), but needs documentation and possible repeat testing.
- Infectious disease screening — HIV, Hepatitis B surface antigen, Hepatitis C antibody, RPR/VDRL, and for patients born in or who have lived in Zika-endemic areas, Zika testing per current CDC guidelines. FDA tissue banking regulations require these screens, and they must be current within specific timeframes for sperm banking, egg freezing, and embryo creation. Your intake form should capture dates and results of existing screens and flag what needs to be repeated.
- Male partner labs — semen analysis (from a CLIA-certified andrology lab, not a general lab), hormonal panel if indicated (testosterone, FSH, LH, prolactin, estradiol), and infectious disease screening matching the female partner's panel. If the couple is using the male partner's sperm, FDA tissue banking exemptions apply for sexually intimate partners, but the screening documentation still needs to exist in the chart.
- Genetic carrier screening — whether expanded carrier panel has been completed, results, and which lab performed it. Different labs test for different numbers of conditions (from 3 to 300+), so knowing the panel used is as important as knowing the results.
Genetic screening and family history assessment
Genetics plays a dual role in fertility care: it informs reproductive risk counseling, and it drives decisions about PGT (preimplantation genetic testing) that can change the cost and complexity of an IVF cycle by thousands of dollars. The intake form must capture enough genetic history to determine whether referral to a genetic counselor is indicated before treatment begins:
- Ethnic background — certain conditions have higher carrier frequencies in specific populations. Ashkenazi Jewish ancestry triggers screening for Tay-Sachs, Canavan disease, familial dysautonomia, and over a dozen other conditions. Mediterranean ancestry increases the relevance of thalassemia screening. African ancestry raises sickle cell screening priority. The intake form should ask about ethnic background for both partners to guide which expanded carrier panels are most relevant.
- Family history of genetic conditions — known genetic diagnoses in first- and second-degree relatives on both sides. Cystic fibrosis, spinal muscular atrophy, fragile X syndrome, Huntington disease, hereditary cancer syndromes (BRCA1/2, Lynch syndrome). A family history of fragile X is particularly relevant because female carriers may have diminished ovarian reserve and premature ovarian insufficiency — it connects genetic screening directly to fertility diagnosis.
- Recurrent pregnancy loss history — two or more first-trimester losses trigger karyotype analysis of both partners to screen for balanced translocations or other structural chromosomal abnormalities. If a translocation is identified, PGT-SR (structural rearrangement) becomes part of the IVF plan, and the patient needs to understand that before consenting to treatment.
- Previous children with genetic conditions or birth defects — this information changes counseling about PGT-M (monogenic disorder testing) and may indicate the need for a custom PGT probe, which takes weeks to develop and must be ordered before the IVF cycle begins.
- Consanguinity — this question is clinically necessary and must be asked without judgment. Consanguineous couples have a higher risk of autosomal recessive conditions, and expanded carrier screening becomes more urgent.
Consent documentation: IVF, IUI, egg freezing, and embryo storage
Consent in reproductive medicine is more complex than in most other medical specialties because the decisions involve potential human life, future reproductive capacity, and legal agreements that may be tested under circumstances the patient cannot anticipate — divorce, death, incapacitation. The intake process must lay the groundwork for informed consent, even though the detailed consent forms themselves are typically signed later in the treatment process:
- Treatment modality understanding — before formal consent, the intake form should document that the patient has received information about the proposed treatment (IUI, IVF, ICSI, FET, egg freezing), understands the basic process, and has been advised of success rates applicable to their age and diagnosis. This is not the consent itself — it is the documentation that the consent conversation started at intake, not five minutes before egg retrieval.
- Multi-fetal pregnancy risk acknowledgment — ASRM guidelines on embryo transfer numbers are clear, but patients need to understand that even single embryo transfer carries a small risk of identical twinning, and that multi-fetal pregnancy carries specific medical risks. The intake should document that this topic was introduced.
- Cryopreservation intent — will the patient be freezing eggs, sperm, or embryos? Each has different consent requirements. Embryo cryopreservation, in particular, requires disposition decisions that must be made before embryos are created. The intake form captures the intent so the appropriate consent documents can be prepared.
- Storage terms and fees — annual embryo storage fees, payment terms, what happens if the patient stops paying, and the clinic's policy on embryo abandonment. These are not just financial details — they are the subject of litigation nationwide, and your documentation needs to be unambiguous.
- Disposition of cryopreserved materials — this is the single most legally consequential section of any fertility clinic intake. The patient (or both partners) must indicate their preferred disposition for frozen embryos in the event of: divorce or dissolution of the relationship, death of one partner, death of both partners, completion of family building, or discontinuation of storage. Options typically include: thaw and discard, donate to research, donate to another patient/couple, or continued storage. Every option must be explicitly chosen, not defaulted. Courts across the country have issued conflicting rulings on embryo disposition disputes, and the strength of the clinic's documentation is often the deciding factor.
Third-party reproduction documentation: donors and surrogates
When treatment involves gamete donors, embryo donors, or gestational carriers, the documentation requirements multiply. The intake form for third-party reproduction cases must capture information that goes beyond standard medical history into legal, psychological, and regulatory territory:
Donor gamete cases (egg donor, sperm donor)
- Donor type — known donor (friend or family member), anonymous donor (through an agency or bank), or directed donor. Each type has different FDA screening requirements, different legal implications, and different psychological counseling recommendations.
- Donor screening status — has the donor completed FDA-mandated infectious disease testing within the required timeframe? Has the donor completed genetic screening? Has the donor had a psychological evaluation? For known donors, has independent legal counsel been obtained? Your intake form needs to track all of these as a checklist, because missing any one of them can halt a cycle that has already involved significant expense and emotional investment.
- Legal agreements — status of the donor agreement (not yet started, in process, executed). For known donors, this is essential because without a properly executed donor agreement, the donor may have parental rights to any resulting child depending on state law. The intake form captures the status; the legal work happens with reproductive law attorneys.
- Donor medical and genetic history — captured through the donor's own intake process, but the intended parent's intake form should document which donor was selected, what screening has been completed, and whether the intended parents have reviewed the donor's genetic carrier screening results in the context of their own carrier status.
Gestational carrier (surrogate) cases
- Carrier identification and screening status — has the gestational carrier been medically cleared by the RE? Has she completed psychological screening? Has she had a hysteroscopy or saline sonogram to evaluate the uterine cavity? Has she completed infectious disease testing?
- Legal agreement status — gestational carrier agreements must be executed before embryo transfer in most states. Some states (Michigan, Louisiana) prohibit compensated surrogacy entirely. Some states (California, Nevada, Connecticut) have favorable surrogacy statutes. Your intake form needs to capture the state of residence of both the intended parents and the carrier, because jurisdiction determines the legal framework.
- Insurance coverage for the carrier — does the gestational carrier's health insurance cover a surrogate pregnancy, or does a separate policy need to be obtained? Some insurance policies have explicit surrogacy exclusions. This is a financial and logistical issue that should be identified at intake, not discovered during the pregnancy.
- Parentage order timeline — pre-birth parentage orders are available in some jurisdictions and must be filed before delivery. Post-birth orders are required in others. The intake form captures the jurisdictional information needed to plan the legal timeline alongside the medical one.
Psychological screening requirements
ASRM recommends psychological consultation for all patients undergoing IVF, and requires it for patients involved in third-party reproduction (donors, recipients, and gestational carriers). The intake form needs to capture the psychological readiness assessment, not as a checkbox, but as a substantive clinical document:
- Mental health history — current and past diagnoses (depression, anxiety, PTSD, eating disorders, bipolar disorder, OCD), current medications (especially SSRIs and other psychotropic medications that may interact with fertility treatments or raise teratogenicity concerns), and current mental health treatment (therapist, psychiatrist, frequency of sessions).
- Fertility-specific psychological factors — duration of infertility and its emotional impact, relationship stress related to treatment, previous traumatic pregnancy experiences (stillbirth, TFMR, neonatal loss), history of perinatal mood disorders, and coping strategies. A patient with a history of severe postpartum depression after her first child needs a different support plan than a patient experiencing infertility for the first time.
- Decision-making capacity for high-stakes choices — embryo disposition, selective reduction, disclosure to donor-conceived children, and the emotional implications of treatment failure. The psychological screening at intake is not a gatekeeping exercise — it is an identification of patients who may benefit from additional support during the treatment process.
- Relationship assessment for couples — are both partners aligned on treatment goals? Is there pressure from one partner to pursue treatment the other is ambivalent about? Are there unresolved disagreements about family size, genetic testing, or disposition decisions? These issues surface during treatment and can derail a cycle emotionally and legally. Better to identify them at intake.
- Third-party reproduction psychological evaluation — for donors: motivation, understanding of the process, feelings about potential future contact from donor-conceived individuals. For gestational carriers: motivation, previous pregnancy experience, family support, understanding of the medical risks, and clarity about the relinquishment process. For intended parents using donors or carriers: feelings about genetic asymmetry (when one partner is genetically related and the other is not), disclosure plans, and expectations about the relationship with the donor or carrier post-birth.
Financial counseling and insurance pre-authorization
Fertility treatment is expensive, variably covered by insurance, and financially devastating when patients are surprised by costs mid-cycle. The intake process must establish financial transparency before treatment begins:
- Insurance fertility benefit verification — does the patient's insurance cover diagnostic testing, IUI, IVF, medications, PGT, cryopreservation, or FET? What are the lifetime maximums? Are there cycle limits? Is there a shared-risk or refund program available? Many states have fertility insurance mandates (Illinois, Massachusetts, Connecticut, New Jersey, Maryland, and others), but the scope of mandated coverage varies dramatically. A patient in New Jersey may have coverage for up to four IVF cycles. A patient in a non-mandate state may have zero coverage. Your intake form needs to capture the insurance details so your financial counselor can verify benefits before the patient assumes coverage exists.
- Prior authorization requirements — many insurers require prior authorization for IVF, and the authorization process can take weeks. Identify this at intake so the authorization is in place before the cycle starts, not holding up a retrieval.
- Out-of-pocket cost estimates — does the patient understand the potential total cost of a cycle including medications ($3,000-$7,000 for a standard IVF stimulation), monitoring ($1,500-$3,000), retrieval ($5,000-$10,000), anesthesia, ICSI ($1,500-$3,000), PGT ($3,000-$6,000 for a biopsy plus per-embryo testing), embryo transfer, cryopreservation ($1,000-$1,500), and annual storage ($500-$1,000/year)? The intake form should document that the patient has received and reviewed a financial estimate.
- Medication coverage and pharmacy coordination — fertility medications are often covered under the pharmacy benefit, not the medical benefit, and may require a specialty pharmacy. Identify the patient's pharmacy benefit, preferred specialty pharmacy, and any prior authorization requirements for medications at intake so the first prescription does not trigger a two-week delay.
- Payment plan or financing arrangements — does the practice offer payment plans? Has the patient applied for or been approved for healthcare financing (Prosper Healthcare Lending, CapexMD, Future Family)? Is the patient participating in a shared-risk/refund program? Capture the financial arrangement at intake so billing is not chasing answers during the cycle.
Medication protocol tracking and compliance
Fertility medication protocols are complex, time-sensitive, and involve multiple injectable medications with overlapping schedules. A patient who misses a dose of Lupron, takes the wrong dose of Gonal-F, or triggers with Ovidrel twelve hours late can compromise an entire cycle. The intake form establishes the baseline for medication management:
- Current medications — everything the patient takes, including prescription medications, over-the-counter drugs, supplements, and herbal preparations. Certain supplements (DHEA, CoQ10, vitamin D) are commonly recommended in fertility contexts but can interact with stimulation protocols. Metformin may be continued or started for PCOS patients. Thyroid medication may need dose adjustment. Document it all.
- Previous medication reactions — has the patient had side effects from fertility medications in previous cycles? Headaches from Lupron, injection site reactions from PIO (progesterone in oil), nausea from estrogen supplementation, OHSS from gonadotropins? These reactions inform protocol modifications.
- Self-injection comfort and training needs — has the patient administered subcutaneous or intramuscular injections before? Does she have a partner or support person who can assist with IM injections (PIO)? Does she need injection training, and if so, when is it scheduled? A patient who is terrified of needles needs a different onboarding experience than a nurse who has been giving herself Lupron for endometriosis for two years.
- Pharmacy coordination — which specialty pharmacy will fill the medications? Has the prescription been sent? Has the patient received her medication shipment and verified the contents? Has she been instructed on proper storage (refrigeration requirements for gonadotropins)? All of this is documented beginning at intake and tracked through the cycle.
- Drug allergy and sensitivity review specific to fertility medications — allergies to progesterone (some patients react to the oil vehicle in PIO — sesame oil vs. ethyl oleate matters), sensitivity to adhesive (for estrogen patches), allergy to latex (relevant for ultrasound probe covers during monitoring), and any history of OHSS, which is not an allergy but requires protocol modification to prevent recurrence.
FDA tissue banking regulations and documentation
Fertility clinics operate under FDA regulations governing human cells, tissues, and cellular and tissue-based products (HCT/Ps) under 21 CFR Parts 1270 and 1271. These regulations are not optional, they are not suggestions, and the documentation requirements are specific. Your intake process must capture the information needed for FDA compliance:
- Donor eligibility determination — for any reproductive tissue that will be used in another person (donor sperm, donor eggs, donor embryos), the donor must be determined eligible based on screening and testing for relevant communicable disease agents and diseases. The screening includes a medical history interview, physical examination, and laboratory testing (HIV 1/2, Hepatitis B, Hepatitis C, syphilis, chlamydia, gonorrhea, and for donors of cells from birth tissue, HTLV I/II). Your intake form captures the donor's screening status and test results.
- Sexually intimate partner exception — when reproductive tissue is used between sexually intimate partners (husband's sperm for wife's IUI, for example), the FDA exempts them from donor eligibility requirements under 21 CFR 1271.90. However, this exemption requires documentation that the partners are sexually intimate, and the tissue must be labeled as such ("NOT EVALUATED FOR INFECTIOUS DISEASES" or "FOR DIRECTED REPRODUCTIVE USE ONLY"). Your intake form should capture the relationship status to determine whether this exemption applies.
- Tissue tracking and labeling — every cryopreserved specimen (sperm, eggs, embryos) must be traceable from creation through storage through use or disposition. The intake form establishes the identity verification chain. Patient name, date of birth, unique clinic identifier, and specimen type must be consistent across all documentation from intake through disposition.
- Adverse reaction reporting — the FDA requires reporting of adverse reactions related to HCT/Ps. If a patient has a history of adverse reactions to donor tissue (infection transmission, allergic reaction), this must be captured at intake and reported if not previously reported.
- State-level requirements beyond FDA — some states impose additional tissue banking requirements. New York, for example, has specific regulations through the New York State Department of Health that exceed federal requirements. California has additional consent requirements for research use of reproductive tissue. Your intake form needs to be compliant with both federal and state requirements, and the state-specific elements should be identified at intake based on the patient's and the clinic's jurisdiction.
LGBTQ+ family building documentation considerations
LGBTQ+ patients and couples face unique documentation requirements in fertility care, not because their clinical needs are fundamentally different, but because the legal framework, insurance landscape, and family formation pathways involve additional complexity that must be captured at intake:
- Family structure documentation — your intake form must accommodate diverse family structures without defaulting to heteronormative assumptions. "Partner" rather than "husband/wife" as a field label. Fields for both intended parents regardless of sex or gender. Acknowledgment that a single individual may be pursuing treatment without a partner. These are not just sensitivity considerations — they affect legal parentage, insurance billing, and consent documentation.
- Same-sex female couples — both partners may undergo evaluation (one may carry, one may provide eggs in reciprocal IVF). Document which partner will undergo which procedure, whether both partners will be evaluated for egg quality and uterine receptivity, and whether the couple has a preference for which partner carries. Both partners' medical histories are clinically relevant even when only one will undergo the procedure.
- Same-sex male couples — treatment involves both an egg donor and a gestational carrier. Documentation requirements include the donor agreement, the carrier agreement, both intended fathers' genetic screening and infectious disease testing (for sperm), and the legal parentage pathway, which varies dramatically by state. Some states allow both intended fathers on the birth certificate through a pre-birth order. Others require a stepparent adoption by the non-genetic father.
- Transgender and nonbinary patients — fertility preservation before gender-affirming hormone therapy or surgery is a time-sensitive clinical need. The intake form must capture current hormone therapy (testosterone, estrogen), duration of use, surgical history (orchiectomy, hysterectomy, mastectomy), and desired fertility preservation pathway (egg freezing, sperm banking, embryo creation). Gender-affirming hormone therapy must typically be discontinued before ovarian stimulation, and the timeline for that discontinuation and recovery of ovarian function must be discussed and documented at intake.
- Insurance coverage gaps — many fertility insurance mandates define infertility based on heterosexual intercourse failure ("inability to conceive after 12 months of unprotected intercourse"). Same-sex couples, single individuals, and transgender patients may not meet this definition, creating insurance coverage gaps even in mandate states. Some states (California, New York, Colorado, Illinois as of recent amendments) have updated their mandates to include inclusive definitions. Your intake form should capture the insurance status and flag potential coverage issues so financial counseling can address them before treatment begins.
- Legal parentage complexity — for any LGBTQ+ family building case, document the intended parentage plan and the legal steps required in the relevant jurisdiction. This information feeds into the consent process and ensures that legal agreements (donor contracts, carrier agreements, pre-birth parentage orders) are initiated early enough in the process to be completed before they are needed.
Disposition of embryos and reproductive material
This topic was introduced in the consent section above, but it deserves its own detailed treatment because it is the source of more legal disputes, ethical dilemmas, and patient distress than any other aspect of fertility documentation. The 2024 Alabama Supreme Court ruling that classified frozen embryos as "extrauterine children" under state law brought embryo disposition to national attention, but fertility clinics have been navigating this issue for decades:
- Embryo disposition elections — at intake, both partners (or the individual patient) must indicate their preference for embryos in the following scenarios: treatment success (family complete), treatment discontinuation (choosing to stop before success), relationship dissolution (divorce or separation), death of one partner, death of both partners, inability to pay storage fees, and loss of contact with the clinic. For each scenario, options should include: continued storage, thaw and discard, donate to another patient or couple, donate to research, and (in some cases) compassionate transfer (transfer with no intent to achieve pregnancy, allowing natural demise).
- Agreement between partners — both partners must agree on the disposition elections. If they disagree, this must be documented and resolved before embryos are created. The intake form should capture each partner's individual preference and flag discrepancies for discussion with the physician and, potentially, the psychological counselor.
- Annual reaffirmation — many clinics require annual reaffirmation of disposition elections, and the initial intake form should inform patients of this requirement. Life circumstances change — a couple that intended to donate unused embryos to research at intake may feel differently after going through a cycle and seeing their embryo images.
- Legal enforceability — the intake form should note that disposition agreements may or may not be legally enforceable depending on jurisdiction, and recommend that patients consult with a reproductive law attorney if they have questions about the legal status of their disposition elections. The clinic is not providing legal advice, but it is providing documentation that may be used in legal proceedings.
- Sperm and egg disposition — similar elections apply to cryopreserved sperm and eggs, though the legal and ethical complexity is somewhat lower because these are gametes, not embryos. Nevertheless, clear disposition documentation prevents confusion and potential disputes, especially for patients who are banking sperm or eggs before cancer treatment, gender transition, or military deployment.
Bringing it all together: building the clinical record from day one
A fertility clinic intake form is not a single document — it is typically a packet of interconnected forms that collectively establish the medical, psychological, legal, financial, and regulatory foundation for treatment. The reproductive history questionnaire feeds the diagnostic workup. The genetic screening assessment triggers referrals. The consent initiation document feeds the formal consent process. The financial verification triggers insurance authorization. The disposition elections feed the cryopreservation consent. The third-party reproduction checklist feeds the legal and psychological screening timelines.
When any piece of this intake process is missing or incomplete, the consequences downstream are disproportionate. A missed carrier screening result means a cycle proceeds without PGT that should have been offered. An incomplete disposition form means embryos are created without clear instructions for their future. A skipped insurance verification means a patient receives a $25,000 bill she thought was covered. A missing FDA screen means the clinic is out of regulatory compliance for tissue banking.
The practices that get this right treat intake as a clinical process, not an administrative one. The intake coordinator is trained in reproductive medicine, not just form processing. The forms are designed for the specific clinical, legal, and regulatory requirements of reproductive endocrinology, not adapted from a general gynecology template. And the information captured at intake flows directly into the treatment plan, the consent process, the billing workflow, and the compliance documentation that the practice needs to operate safely and legally.
For a deeper look at how healthcare documentation systems work across specialties, including the HIPAA compliance requirements that apply to all of these forms, see our guide to HIPAA-compliant intake forms and the broader Healthcare Bundle that covers 21 healthcare categories with profession-specific intake documentation.
Professional healthcare intake forms — built for clinical environments
Fillable PDF intake forms and client questionnaires designed for healthcare practices. Reproductive history, patient demographics, insurance verification, consent documentation, HIPAA compliance, and specialty-specific clinical fields.